Alpha-amylase variants with altered properties
The present invention relates to variants (mutants) of polypeptides, in particular Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca2+ dependency, specific activity, in particular laundry and dish-wash applications.
1. A variant of a parent Termamyl-like alpha-amylase, comprising an alteration at one or more positions selected from the group of: 30, 33, 37, 106, 118, 128, 133, 149, 150, 160, 178, 193, 203, 214, 256, 257, 270, 272, 283, 298, 299, 303, 304, 305, 314, 315, 319, 339, 345, 361, 378, 419, 421, 441, 444, 445, 447, 450, 461, 471, 482, 484, wherein (a) the alteration(s) are independently (i) an insertion of an amino acid downstream of the amino acid which occupies the position, (ii) a deletion of the amino acid which occupies the position, or (iii) a substitution of the amino acid which occupies the position with a different amino acid, (b) the variant has alpha-amylase activity, and (c) each position corresponds to a position of the amino acid sequence of the parent Termamyl-like alpha-amylase having the amino acid sequence of SEQ ID NO: 12, wherein the variant has an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 12.
2. The variant of claim 1 , wherein the mutations are: 30N, 128Y, 133A, 149N, 150Q, 160F, 193S, 203L, 214I,T, 256K, 257I, 270D, 272I,V,A, 298H, 299F,Q,T, 303Q,K, 304F,R,K, 314D,S,Q, 315N, 319K,S, 339S, 361E, 421Y, 444E,Y, 450T, 461P, 471E, 482Y, or 484Q.
3. The variant of claim 1 , wherein the mutations are: D30N, N128Y, G133A, G149N, N150Q, Y160F, T193S, Y203L, V214I,T, G256K, T257I, N270D, L272I,V,A, Y298H, N299F,Q,T, S303Q,K, Y304F,R,K, N314D,S,Q, G315N, Q319K,S, A339S, Q361E, H421Y, R444E,Y, V450T, T461P, N471E, W482Y, or N484Q.
4. The variant of claim 1 , wherein the mutations are: N33D, K37T, N106D, K118Q, G133E, G149A, N150H, Y178F, T193N,D,E,Q, N270F,Y, N283D, Y298F, N299Y, G305D, N314T, G315S,T, Q319E,T, A339T, E345N,R, G378K, T419N, F441L, N445Q, A447Y.
5. The variant of claim 1 , wherein the variant has an additional mutation in one or more methionine residues.
6. The variant of claim 5 , wherein the methionine residues are: M9, M10, M116, M202, M208, M261, M309, M323, M382, M410, M430, and M440.
7. The variant of claim 6 , wherein the mutations are: M9L,I, M10L, M105L,I,F, M116N, D,L,I,F,W,R,K, M202I, L,V,T, M208F,Y,L,I, M261L,I, M309L,I, 1323L,I,S,T,A,Q,E,N,D, 1382L,I,Y,F,K, M410L,I,V, M430L,I, and M440L,I,F,Y.
8. The variant of claim 1 , wherein the variant has one or more of the following mutations: M9L+M202I, M9L+M202I+M323T, M9L+M202I+323T+M382Y, M9L+M202I+A339S, M9L+M202L, M9L+M202L+M323T, M9L+M202L+M232T+M382Y, M9L+M202L+A339S, M9L+M202T, M9L+M202T+M323T, M9L+M202T+M323T+M382Y, M202L+M105F+M208F, G133E+M202L+Q361 E, G133E+M202L+R444E, M202L+M323T+M309L, M202L+M323T+M430I, M202L+V214T+R444Y, M202L+N283D+Q361 E, G133E+M202I+Q361 E, G133E+M202I+R444E, M202I+M202I+M323T, M202I+M202I+M323T+M309L, M202I+M323T+M430I, M202I+V214T+R444Y, M202I+N283D+Q361 E, M202V+M105F+M208F, G133E+M202V+Q361 E, G133E+M202V+R444E, M202V+M323T, M202V+M323T+M309L, M202V+M323T+M430I, M202V+M323T+M9L, M202V+V214T+R444Y, M202V+N283D+Q361 E, M202T+M105F+M208F, G133E+M202T+Q361 E, G133E+M202T+R444E, M202T+A339S, M202T+M323T, M202T+M323T+M309L, M202T+M323T+M430I, M202T+M323T+M9L, M202T+V214T+R444Y, M202T+N283D+Q361 E, M202T+A339S, M202T+N299F,Y.
9. The variant of claim 1 , wherein the variant further comprises the mutation D183 ss+G184 ss.
10. The variant of claim 1 , wherein the variant further comprises a mutation in R118.
11. The variant of claim 1 , wherein the variant further comprises a mutation in N195.
12. The variant of claim 1 , wherein the variant further comprises a mutation in R320.
13. The variant of claim 1 , wherein the variant further comprises a mutation in R458.
14. The variant of claim 1 , wherein the variant comprises the mutation D183ss+G184ss+R118K+N195F+R320K+R458K in combination with one or more of the following mutations: K118Q, K37T, H421Y, V450T, N445Q, Y178F, W482Y, N283D+Q361 E, M105F+M208F, M202L+M323T+M430I, R444Y, N106D, Y203L, G133E+Q361E, M323E, V214T, M202L+M323T+M309L, M202L, M202L+M323T, M202L+M323T+M9L+M382Y, M202L+M323T+M9L.
15. The variant of claim 14 , wherein the variant comprises the mutation D183ss+G18455+R118K+N195F+R320K+R458K+M202L+M323T+M9L.
16. The variant of claim 15 wherein the variant further comprises one or more of the following mutations: T461 P, Y298H, G133E+R444E, Y298F, M202T, M202I, M202V, Y160F+V214T+M382Y R82H+N128Y+G149A+V214T+M382Y N150H+V214T V214T+E345N V214T+G305D+M382Y+R444E V214T+M382Y+A447Y V214T+G378K V214T+A256K.
17. The variant of claim 1 , wherein the parent Termamyl-like alpha-amylase is derived from a strain of B. licheniformis, B. amyloliquefaciens, B. stearothermophilus, Bacillus sp. NCIB 12289, NCIB 12512, NCIB 12513 or DSM 9375, or DSMZ no. 12649, KSM AP1378, or KSM K36 or KSM K38.
18. The variant of claim 1 , which variant has an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH activity profile, pH stability profile, stability towards oxidation, Ca 2+ dependency, reduced and increased pi and improved wash performance, specific activity, stability under high temperature and/or low/high pH conditions, optionally at low calcium concentrations, and stability in the presence of detergent.